<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-695X</journal-id>
<journal-title><![CDATA[Revista Clínica de Medicina de Familia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Clin Med Fam]]></abbrev-journal-title>
<issn>1699-695X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Medicina de Familia y Comunitaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-695X2020000200012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Penfigoide ampolloso secundario a vildagliptina]]></article-title>
<article-title xml:lang="en"><![CDATA[Bullous pemphigoid secondary to vildagliptin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Ibáñez]]></surname>
<given-names><![CDATA[Rosa Mar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Jiménez]]></surname>
<given-names><![CDATA[María Soledad]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Molina]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrasco Barrio]]></surname>
<given-names><![CDATA[Yolanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Salud de Santa María de Benquerencia  ]]></institution>
<addr-line><![CDATA[Toledo ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Salud de Santa María de Benquerencia  ]]></institution>
<addr-line><![CDATA[Toledo ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>13</volume>
<numero>2</numero>
<fpage>162</fpage>
<lpage>165</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-695X2020000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-695X2020000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-695X2020000200012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El penfigoide ampolloso es una enfermedad autoinmune caracterizada por presencia de lesiones urticariformes o eccematosas muy pruriginosas sobre las que posteriormente pueden aparecer ampollas tensas de contenido seroso o hemorrágico. Planteamos un caso clínico de un paciente con penfigoide ampolloso secundario a vildagliptina. Aunque el diagnóstico definitivo se realiza mediante dos biopsias cutáneas, en nuestro caso, dada la alta sospecha clínica, comenzamos con tratamiento con corticoides y suspendimos la vidagliptina con resolución del cuadro en pocas semanas. Nos parece interesante no solo por el diagnóstico en sí, sino también para destacar la importancia del papel del médico de familia en este tipo de enfermedades tanto a nivel del diagnóstico como del seguimiento de la evolución y del tratamiento. Y por otra parte para resaltar la utilidad de las nuevas tecnologías, como la teledermatología.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Bullous pemphigoid is an autoimmune disease characterised by presence of very pruritic hives-like or eczema-like lesions on top of which serum- or blood-containing tense blisters can later appear. We present the clinical case of a patient with bullous pemphigoid secondary to vildagliptin. Although the definitive diagnosis is made by two skin biopsies, in this case, given high clinical suspicion, we began treatment with corticosteroids and discontinued vildagliptin, with complete resolution in a few weeks. This case is interesting not only for its diagnosis, but also to highlight the importance of the role of the family doctor in this type of diseases, in diagnosis and in the follow-up and treatment. And also to emphasise the usefulness of new technologies, like teledermatology.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Penfigoide Ampolloso]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de la Dipeptidil-Peptidasa IV]]></kwd>
<kwd lng="es"><![CDATA[Medicina Familiar y Comunitaria]]></kwd>
<kwd lng="es"><![CDATA[Telemedicina]]></kwd>
<kwd lng="en"><![CDATA[Pemphigoid, Bullous]]></kwd>
<kwd lng="en"><![CDATA[Dipeptidyl-Peptidase IV Inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Family Practice]]></kwd>
<kwd lng="en"><![CDATA[Telemedicine]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuertes de Vega]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Iranzo-Fernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marcaró-Galy]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Penfigoide ampolloso: guía de manejo práctico]]></article-title>
<source><![CDATA[Actas Dermo-Sifiliogr]]></source>
<year>2014</year>
<volume>105</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>328-46</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Amagai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune bullous diseases: historical perspectives]]></article-title>
<source><![CDATA[J Invest Dermatol]]></source>
<year>2008</year>
<volume>128</volume>
<numero>E3</numero>
<issue>E3</issue>
<page-range>E16-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dungan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[DeSantis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dipeptidyl peptidase-4 (DPP-4) inhibitors for the tratment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[UpToDate]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Whaltman (MA) ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benzaquen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borradori]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Berbis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cazzaniga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Richard]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2018</year>
<volume>78</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1090-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of dipeptidyl peptidase 4 inhibitors use with risk of bullous pemphigoid in patients with diabetes]]></article-title>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2019</year>
<volume>155</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kridin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients]]></article-title>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2018</year>
<volume>154</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1152-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
